ESPL1 and cancer: Our findings indicate that higher levels of SEC31A1 are positively associated with increased IC50 values of cancer therapy drugs, whereas the expression of TOPBP1, ESPL1, and CPSF3 displayed an opposite correlation (Figure 3A).